Skip to content
Matrix Global Advisors
Matrix Global Advisors
  • Home
  • About
  • News
  • Our Work
  • Contact
  • Home
  • About
  • News
  • Our Work
  • Contact
Sep52018
Analysis

New MGA Study Estimates Lost Savings from Misuse of REMS and Restricted Access Programs

A new study from MGA examines the practice by brand drug manufacturers of using Risk Evaluation and Mitigation Strategies (REMS) and other forms of restricted access to keep generic manufacturers from obtaining samples needed to develop generic drugs. MGA estimates that this misuse blocks $13.4 billion in generic savings annually, an estimate that has grown nearly 250 percent since MGA’s 2014 analysis of this issue.

Read Here

September 5, 2018Category: Analysis

Post navigation

PreviousPrevious post:New MGA Paper Identifies Steps to Reducing Barriers to BiosimilarsNextNext post:MGA’a Alex Brill on WXTK’s ‘Something More with Chris Boyd’
  • Analysis(29)
  • Books(2)
  • Events(13)
  • Interviews(37)
  • News(46)
  • Op-Eds(63)
  • Press Releases(2)
  • Testimony(19)
  • Alex Brill Talks Trade Disruption Due to Suez Canal Blockage on i24 News
    March 31, 2021
  • Alex Brill Featured in Foundation for Economic Education Article
    March 26, 2021
  • U.S. Spending and Tax Policy After the COVID Recessions: Political Economy Podcast
    March 24, 2021
  • Alex Brill Testifies Before U.S. Senate on Lowering Prescription Drug Prices
    March 23, 2021

Website Design and Developed by DreamBig Creative